Mitofusin activators extend lifespan in C. elegans worms
In the roundworm C. elegans, blocking the mitofusin protein FZO-1 shortened lifespan, while two mitofusin activators lengthened survival; the effect of Chimera required FZO-1. These are proof-of-concept worm studies, not evidence of human benefit. [1]
Automatic summary · not editorially reviewed
The key findings
Adding the mitofusin inhibitor MFI8 to age-synchronized C. elegans cultures shortened lifespan in a concentration-dependent manner. [1]
The mitofusin activators Chimera and 8015-P2 prolonged worm survival in a dose-dependent manner, and Chimera's effect was absent in worms lacking FZO-1. [1]
The authors call these proof-of-concept worm studies and suggest 8015-P2, under development for human neurodegenerative diseases, might alleviate aging phenotypes in higher species. [1]
The source at a glance
- Study type / format
- Preclinical experimental study in worms (abstract)
- Population / context
- Age-synchronized Caenorhabditis elegans roundworms, including worms lacking FZO-1 or DRP-1.
- Summary based on
- Study abstract
- Original publication
- September 30, 2026
Worm lifespan with mitofusin inhibitor MFI8
The authors start from the idea that age-linked tissue dysfunction goes with mitochondrial degeneration, seen as fragmented organelles and poor respiration. They tested this in age-synchronized C. elegans roundworms, whose mitochondrial fusion depends on the mitofusin ortholog Fuzzy Onion-1 (fzo-1). Adding the mitofusin inhibitor MFI8 to worm cultures shortened lifespan, and the shortening depended on concentration.
Supporting source [1]
Chimera and 8015-P2 survival effects in worms
In the opposite direction, the mitofusin activators Chimera and 8015-P2 prolonged worm survival in a dose-dependent way. Chimera's pro-survival effect was absent in worms lacking its protein target, FZO-1. At lower concentrations, the survival gain from Chimera was further increased when the mitochondrial fission protein DRP-1, which acts in opposition to fzo-1, was absent. The more potent activator 8015-P2 showed greater anti-aging effects on lifespan and improved healthspan, measured as forced swimming activity and resistance to thermal and oxidative stress.
Supporting source [1]
Proof-of-concept scope and higher-species outlook
The authors describe these as proof-of-concept worm studies that identify aging phenotypes reciprocally related to fzo-1/mitofusin activation status. They note that 8015-P2 is under development for use in human neurodegenerative diseases and suggest it might alleviate aging phenotypes evoked by mitochondrial degeneration in higher species. That is a proposed possibility, not a demonstrated human lifespan or health benefit.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. All results come from C. elegans roundworms, and the suggestion about higher species is a proposed possibility, not a demonstrated human outcome.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Weigele J, Zhang L, Li J, Roider E, Walton CE, Dorn GW. · europepmc.org · September 30, 2026